Trial · NCT02312063
Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes
NCT02312063, Phase 4, Completed, Kansai Electric Power Hospital; results first posted 2019-07-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes. Trials, record NCT02312063. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02312063
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes
- NCT number
- NCT02312063
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 48 participants, actual
- Lead sponsor
- Kansai Electric Power Hospital
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Sitagliptin, Glimepiride
- First posted
- 2014-12-09
- Last updated
- 2019-07-01
- Results first posted
- 2019-07-01
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Correlation of Plasma Levels of EPA and DHA With HbA1c Reduction | 0-16 weeks | Pearson's correlation coefficient of HbA1c reduction with plasma levels of EPA and DHA at baseline |
| Secondary | Correlation of Estimated Seafood Intake With HbA1c Reduction | 0-16 weeks | Pearson's correlation coefficient of HbA1c reduction with estimated seafood intake |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Correlation of Plasma Levels of EPA and DHA With HbA1c Reduction | 0-16 weeks | pearson's correlation coefficient | NUMBER | |
| SECONDARY | Correlation of Estimated Seafood Intake With HbA1c Reduction | 0-16 weeks | pearson's correlation coefficient | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Correlation of Plasma Levels of EPA and DHA With HbA1c Reduction | Sitagliptin | r (EPA and delta HbA1c) | -0.414 | pearson's correlation coefficient | |
| Correlation of Plasma Levels of EPA and DHA With HbA1c Reduction | Glimepiride | r (EPA and delta HbA1c) | 0.067 | pearson's correlation coefficient | |
| Correlation of Plasma Levels of EPA and DHA With HbA1c Reduction | Sitagliptin | r (DHA and delta HbA1c) | -0.319 | pearson's correlation coefficient | |
| Correlation of Plasma Levels of EPA and DHA With HbA1c Reduction | Glimepiride | r (DHA and delta HbA1c) | 0.093 | pearson's correlation coefficient | |
| Correlation of Estimated Seafood Intake With HbA1c Reduction | Sitagliptin | -0.042 | pearson's correlation coefficient | ||
| Correlation of Estimated Seafood Intake With HbA1c Reduction | Glimepiride | 0.215 | pearson's correlation coefficient |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Sitagliptin | 23 | |
| Overall Study | STARTED | Glimepiride | 25 | |
| Overall Study | COMPLETED | Sitagliptin | 23 | |
| Overall Study | COMPLETED | Glimepiride | 24 | |
| Overall Study | NOT COMPLETED | Sitagliptin | 0 | |
| Overall Study | NOT COMPLETED | Glimepiride | 1 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypoglycemia | Metabolism and nutrition disorders | Sitagliptin | 0 | 23 | 0 |
| other | Hypoglycemia | Metabolism and nutrition disorders | Glimepiride | 5 | 25 | 5 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Sitagliptin | ||
| Total, all-cause mortality | Glimepiride | ||
| Total, other adverse events | Sitagliptin | 0 | 23 |
| Total, other adverse events | Glimepiride | 5 | 25 |
| Total, serious adverse events | Sitagliptin | 0 | 23 |
| Total, serious adverse events | Glimepiride | 0 | 25 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Sitagliptin vs Glimepiride: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02312063
GET https://conductscience.org/api/trials/v1/NCT02312063/registered